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Edited by Takashi GojoboriAbstract To determine if occupancy of interfacial pockets in
oligomeric proteins by volatile anesthetic molecules can alloster-
ically regulate oligomerization equilibria, variants of a three-
helix bundle peptide able to form higher oligomers were studied
with analytical ultracentrifugation, hydrogen exchange and mod-
eling. Halothane shifted the oligomerization equilibria towards
the oligomer only in a mutation predicted to create suﬃcient vol-
ume in the hexameric pocket. Other mutations at this residue,
predicted to create a too small or too polar pocket, were unaf-
fected by halothane. Inhaled anesthetic modulation of oligomer-
ization interactions is a novel and potentially generalizable
biophysical basis for some anesthetic actions.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Volatile anesthetics alter the activity of many biological tar-
gets through as yet poorly deﬁned molecular mechanisms [1,2].
The lack of structural information, and the experimental diﬃ-
culties in handling both the membrane proteins and the vola-
tile anesthetics have thus far prevented the identiﬁcation of
anesthetic binding sites in all but a few such targets [3,4].
Water soluble proteins have therefore been popular model sys-
tems for studying anesthetic binding using X-ray crystallogra-
phy [5,6], photoaﬃnity labeling [7] and ﬂuorescence
spectroscopy [8]. In general, volatile anesthetics bind to preor-
ganized internal cavities with weak amphiphilic character, con-
sistent with the strong correlation of anesthetic potency and
hydrophobicity (Overton/Meyer) [2].
A haloalkane binding site was found at the interface between
human serum albumin domains IIA and IIB [5], and at a do-
main interface in ﬁreﬂy luciferase [6]; in both cases, the native
state of the protein is stabilized against unfolding by the halo-*Corresponding author. Fax: +1 215 349 5078.
E-mail address: roderic.eckenhoﬀ@uphs.upenn.edu (R.G. Eckenhoﬀ).
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doi:10.1016/j.febslet.2004.10.087alkane [9,10]. Thus, occupancy of interfacial sites could regu-
late protein activity allosterically through stabilization of
domain/domain interactions. Extending these interdomain
interactions to those of protein complexes, halothane pro-
motes the oligomerization of SERCA1, the probable basis
for the observed inhibitory activity of the Ca2+ pump [11,12],
and induces co-localization on the membrane of the major his-
tocompatibility complex proteins HLA I and II [13]. These
observations could underscore a general mechanism of volatile
anesthetics: modulation of oligomerization equilibria through
occupancy of interfacial cavities.
We tested this general mechanism in a simple model system.
A series of model proteins were previously designed to form
hexameric complexes in solution [14]. These complexes are
formed as three dimeric three-helix bundles, each with a leu-
cine-rich hydrophobic core, and then further associate through
an exposed aromatic patch on the surface to form the hexamer
with an aromatic ‘‘supercore’’. The polarity and steric bulk of
one of the aromatic residues in the supercore was mutated
systematically to predictably modulate the stability of the
hexamer. These mutations (from phenylalanine (Phe) to isoleu-
cine (Ile), lysine (Lys) and alanine (Ala), respectively) also pre-
dict the formation of a cavity at the two extremities of the
hexameric assembly that might accommodate a ligand. Molec-
ular modeling suggests that the Ala mutant forms a hydropho-
bic cavity that can accommodate halothane (120 A˚3), but in
the Ile mutant, the cavity is too small, and in the Lys mutant, it
is too polar and perhaps too small. Moreover, we hypothesized
that anesthetic occupancy of the Ala mutant cavity would re-
store van der Waals contacts in the hydrophobic ‘‘supercore’’
of the assembly, and thus stabilize the hexameric form of the
protein.2. Methods
2.1. Molecular modeling
Computer models of the hexamers were generated from the crystal
structure of the three-helix bundle, DSD (PDB entry 1G6U), using In-
sight II (Accelrys, Inc. San Diego, CA; www.accelrys.com) as de-
scribed before [14]. Each three-helix bundle is formed by two chains
of amino acids, numbered from 1 to 48 and from 1 0 to 48 0, respectively;
the two other three-helix bundles in each hexameric assembly are re-
ferred to as B (B1–B48 and B1 0–B48 0) and C (C1–C48 and C1 0–ation of European Biochemical Societies.
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within Insight II (cvﬀ forceﬁeld); for Hex-Lys, we built two diﬀerent
models in which diﬀerent rotamer conformations were adopted for
Lys 42 on each of the six chains. Because of the twofold symmetry
in each dimer, identical putative ligand sites are located both at the
top and bottom of the assembly; only one was evaluated by modeling.
Each of the ﬁve models was screened for binding pockets using CASTp
(http://cast.engr.uic.edu/cast/ [15]). This algorithm reports both the sol-
vent (radius = 1.4 A˚) accessible volume (SAV) [16] and molecular sur-
face [17] volumes (MSV). We repeated the calculations with a probe
radius close to the largest dimension of halothane (3.5 A˚). Thus, any
revealed pockets or cavities with non-zero SAV will accommodate hal-
othane in any orientation. Further evaluation of halothanes occu-
pancy employed the Docking module of Insight II. Brieﬂy, a
minimized model of halothane was manually placed in the cavity,
and the ﬁxed Docking program launched to search for optimal place-
ment. For Hex-Ala the binding site comprised residues F28, A42 0, L25,
and E21 for each three-helix bundle (42 0 is the mutated residue across
the series). A multiple start was implemented so that bias from starting
positions would be minimized. Of the four proteins, only Hex-Ala
docked the halothane in an energetically favorable manner. Repeated
simulations resulted in convergence of resultant structures towards an
ensemble of halothane orientations within the cavity; in the conforma-
tion chosen, the interaction energy between the binding region and hal-
othane was 5.3 kcal/mol.
2.2. Hydrogen–tritium exchange
Amide hydrogen exchange protection factors for ‘‘core’’ residues
should be increased in the hexamer as compared to the dimer, so
hydrogen–tritium exchange was used to monitor oligomerization. Pep-
tide solutions (5 mg/ml) were incubated with 5 mCi 3HOH in 1 M
GdnCl, 0.1 M NaH2PO4, pH 8.5, buﬀer for 18 h at 23 C; conditions
intended to assure equilibration of all exchangeable hydrogens prior to
initiation of exchange-out. Free 3HOH was removed, buﬀer ex-
changed, and exchange-out initiated with a PD-10 gel ﬁltration column
(Sigma–Aldrich, St. Louis, MO). After recovery, the protein solution
was transferred to pre-ﬁlled Hamilton (Reno, NV) gas-tight syringes
containing halothane and equipped with repeaters. Aliquots were pre-
cipitated with 2 ml of ice-cold 10% trichloroacetic acid at timed inter-
vals over at least 6 h. The precipitant was vacuum-ﬁltered through
Whatman GF/B ﬁlters (Clifton, NJ) and washed with 8 ml of ice-cold
2% TCA. Tritium retained by the protein was determined by liquidFig. 1. Molecular models of two mutants, Hex-Ala (a) and Hex-Phe (b). Fo
sequences of the four mutants investigated and of the starting dimeric threescintillation. Protection factor ratios (PFRs) were determined for the
last 3–5 hydrogens in common for the two conditions (see ﬁgure leg-
ends), and DDG was determined using DDG = RT ln(PFR).
2.3. Analytical ultracentrifugation
Hex-Ala and Hex-Lys samples75 lM protein in 100 mMNa Phos-
phate buﬀer at pH 7.0 containing either 0 or 10 mM halothane were
centrifuged to equilibrium at 35 (Hex-Ala) or 40 (Hex-Lys) KRPM in a
Beckman XLI instrument using Yphantis-type carbon-epoxy cells. Ra-
dial concentration proﬁles were measured using interference optics
with an eﬀective extinction coeﬃcient of 2.73 fringe-cm3/mg. Data
for the halothane-free Hex-Ala sample and for both Hex-Lys samples
were ﬁt to a monomer–trimer equilibrium considering the dimer to be
the monomeric unit. Data obtained for the Hex-Ala sample in
halothane-saturated buﬀer showed essentially complete trimerization
of the dimer, precluding a measurement of the dissociation constant.3. Results
3.1. Molecular modeling
In each of the three bundles, the residues identiﬁed as part of
the cavity using the 1.4 A˚ probe were F28, A42 0, L25, and E21
(highlighted in Fig. 1a (Hex-Ala) and 1b (Hex-Phe)) (Table 1).
Only Hex-Ala displays a pocket large enough to accommodate
halothane by both SAV and MSV methods; using the 3.5 A˚
probe, only the pockets in Hex-Ala had a non-zero SAV.
All the residues lining the cavity were included in the simu-
lated docking calculations. Of the ﬁve models examined, only
Hex-Ala showed a plausible result for the docking experiment:
several simulations resulted in a convergent low-energy bind-
ing model (Fig. 2). The Hex-Ala/halothane complex was exam-
ined using the CASTp server in order to verify that the external
ligand had eﬃciently ﬁlled the cavity; SAV of 80 A˚3 and MSV
of 523 A˚3 were obtained. These values are comparable with
those of the unliganded Hex-Phe and Hex-Ile mutants. The
Hex-Ala mutant was therefore used to explore the eﬀect of hal-
othane binding on hexamer stabilization.r clarity, one of the three-helix bundles is omitted. Panel (c) shows the
-helix bundle, DSD.
Table 2
Hydrogen–tritium exchange results
Peptide DDG, kcal/mol
Hex-Ala 0.37 ± 0.11
Hex-Lys 0.00 ± 0.0
Hex-Phe 0.00 ± 0.0
Hex-Ile 0.16 ± 0.04
DSD 0.00 ± 0.0
Values are means ± SEM, n = 3.
Table 1
CASTp results for each model in A˚2 (area) and A˚3 (volume) (shown are values for 1.4/3.5 A˚ probe radii)
Model Surface area [16] Surface area [17] SAV [16] MSV [17]
Hex-Phe 126/0 312/0 59/0 350/0
Hex-Ile 199/0 547/0 92/0 569/0
Hex-Ala 306/6 575/238 232/1 809/331
Hex-Lys 100/0 289/0 37/0 279/0
Hex-Lys 2 148/0 728/0 57/0 411/0
Hex-Ala w/Halo 200/0 523/0 80/0 543/0
Fig. 2. Space-ﬁlling model of the halothane/Hex-Ala complex, gener-
ated using the Docking module (Section 2).
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The results, expressed as DDG, are summarized in Table 2.
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Fig. 3. Hydrogen–tritium exchange-out. (a) In Hex-Ala, halothane (7 mM)
mM) had no detectable eﬀect on slow hydrogen exchange rates. Filled symb
required for exchange-out of a given H under native conditions to that for the
of the slowest hydrogens for which there are data.baseline exchange rates were slow, and halothane had no
detectable eﬀect on these rates. Halothane also had no eﬀect
on the more rapid exchange rate of DSD or Hex-Lys, peptides
that form hexamers less readily in solution. In the fully oligo-
merized Hex-Phe, halothane also had no eﬀect on exchange
rates (Fig. 3b, Table 2). On the other hand, for Hex-Ala at
30 lM, where the dimer and hexamer are nearly equimolar,
halothane decreased the exchange rate of slow amide protons
(Fig. 3a and Table 2). For Hex-Ile, a peptide that is
predominantly hexameric at the concentration of the
experiment, halothane produced a slight increase in exchange
rates, corresponding to a destabilization of 0.16 kcal/mol
(Table 2).
3.3. Analytical ultracentrifugation
In the peptide concentration range of the experiment, and
in the absence of halothane, Hex-Ala exists in a dimer–
hexamer equilibrium with a Kd of 2 · 1010 M2. In the pres-
ence of halothane, Hex-Ala sediments as a fully hexameric
single species. The eﬀect of halothane is evident in the raw
data shown in Fig. 4. Given the range of concentrations ex-
plored in the experiment, we estimate that the Kd for the
equilibrium must be lower than 1 · 1013 M2. In contrast,
the Kd similarly determined for the Hex-Lys mutant was
1.2 · 106 M2, a value that did not change signiﬁcantly with
the addition of halothane. Thus, binding of halothane
speciﬁcally to the Hex-Ala mutant shifts the dimer–hexamer
equilibrium towards the hexamer by at least three orders of
magnitude. This technique could not be used to investigate0 100 200 300 400
0
5
0
5
0
5
0
5
utes
)
reduces slow amide hydrogen exchange. (b) In Hex-Phe, halothane (7
ols are halothane and open control. PFR values are a ratio of the time
same H in the presence of the anesthetic. This is repeated for at least 3
76
5
4
3
2
1
Fr
in
ge
 D
is
pl
ac
em
en
t
6.606.556.506.45
R [cm]
Fig. 4. Analytical ultracentrifugation data for Hex-Ala peptide as
described in Section 2. Dots are without halothane and crosses are with
halothane. Lines are ﬁts to data as described in Section 3.
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peptides have Kds lower than 1 · 1013 M2, eliminating an
ability to detect a further stabilization of the hexamer.4. Discussion
We previously found that the number of aromatic residues in
the ‘‘supercore’’ of the oligomeric assembly determines the
aggregation state of the protein; while Hex-Ile and Hex-Phe
form stable hexamers in solution, Hex-Lys and Hex-Ala exist
in a dimer–hexamer equilibrium. The dissociation constant
for hexamer (trimer of dimers) formation correlates with the
polarity of side chain 42. The values calculated by analytical
centrifugation are 1.2 · 107 M2 for Hex-Lys and 6.3 · 1010
M2 for Hex-Ala, respectively [14].
While it was not possible to obtain an exact value for the
Hex-Phe and Hex-Ile mutants, the Kds are estimated to be
lower than 1013 M2. Thus, only mutants that can form a
well-packed supercore assemble into a stable hexamer. If
assembly of the supercore produces packing defects, then the
molecule exists in a dimer–hexamer equilibrium. This system
provides an ideal model of allosteric regulation: in fact, the
mutants populate diﬀerent conformational states, dimer and
hexamer, which are selectively stabilized for each mutant
depending on the hydrophobic nature of a single residue.
We hypothesized that halothane would bind to apolar cavi-
ties at the top and bottom extremities of the Hex-Ala assem-
bly, restoring van der Waals contacts lost by the mutation,
thus shifting the dimer–hexamer equilibrium towards thehexamer. Molecular modeling of the hexameric mutants shows
that halothane can only be accommodated within the Hex-Ala
pocket(s). The SAV of these pockets is 59 A˚3 in Hex-Phe, 91
A˚3 in Hex-Ile, and 57 A˚3 in Hex-Lys. The SAV for Hex-Ala
was 230 A˚3, but when occupied by halothane in our model, this
volume is reduced to 80 A˚3, very similar to the other mutants.
Thus, the ligand appears to bury a comparable hydrophobic
surface, and we predicted rescue of the destabilizing mutation
as has been observed for diﬀerent ligands in other designed sys-
tems [18,19].
Centrifugation and hydrogen exchange experiments show
that halothane stabilizes the Hex-Ala hexamer. The centrifu-
gation experiments suggest a larger free energy change than
that determined by HX, but the direct comparison requires
that exchange-out occur only from the dimeric peptide and
not from the hexameric, a situation known to be invalid.
Both methods also clearly indicate the absence of stabiliza-
tion of Hex-Lys, presumably because of an inadequate pocket
volume, or the introduced full charge [9]. We used DSD, the
parent peptide in the series, essentially unable to form hexa-
mers in solution, as a control for the hydrogen exchange
experiment. Halothane had no eﬀect on HX exchange-out
rates of DSD, indicating an absence of stabilization, and
therefore binding, to the dimer. Therefore, the observed
changes in HX rates for the other peptides are at least in part
due to shifts in the oligomerization equilibria. Finally, HX
data indicate an absence of stabilization and binding to
Hex-Phe, presumably because of the predicted undersized
cavity. Interestingly, molecular modeling predicts the volume
of the Hex-Ile cavity to be slightly lower than the molecular
volume of halothane, and HX indicates a destabilization.
This suggests either binding to the dimer, or to a destabilized
hexamer [20].
The ability of these small hydrophobic molecules to modu-
late protein oligomerization introduces a novel and potentially
generalizable biophysical basis for inhaled anesthetic action.
Suggested in the case of the CaATPase [11,12], modulation
of oligomerization is directly demonstrated in this a-helical
system. It is relevant that the transmembrane topology of the
ligand-gated ion channels, plausible anesthetic targets, is
thought to consist of a-helical bundles non-covalently assem-
bled in the lipid bilayer. Moreover, a large fraction of interfa-
cial pockets in protein complexes is uncomplemented by
contiguous surface, providing the opportunity for small li-
gands to stabilize the complex [21]. Protein–protein interac-
tions underlie much of biology and certainly signaling in the
central nervous system. The widespread and diverse eﬀects re-
ported for the inhaled anesthetics, once thought to reﬂect the
indirect eﬀects of physical perturbations of lipid bilayers,
may actually reﬂect more speciﬁc, but similarly widespread ef-
fects at protein–protein interfaces.References
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